Novartis comes under scrutiny over competition rules
The Competition Commission is investigating pharmaceuticals firm Novartis for anti-competitive practices from 2009 to 2017.
The probe concerns a range of competitive medicines treating macular diseases.
A report found Novartis aimed to prevent market access to competitors.
The commission will consider the report findings at a December 4 meeting.
